SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech fireworks
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Julius Wong8/8/2017 8:12:12 AM
   of 7424
 
FibroGen up 54% premarket on positive mid-stage data on pamrevlumab
  • FibroGen (NASDAQ: FGEN) is up 54% premarket on increased volume in response to its announcement of positive data from a Phase 2 clinical trial assessing anti-connective tissue growth factor antibody pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF).
  • The study met its primary endpoint of demonstrating a statistically valid treatment effect compared to placebo. Specifically, the pamrevlumab cohort experienced an average decline from baseline to week 48 in a measure of lung function called forced vital capacity percent predicted (FVC % predicted) of 2.85 compared to 7.17 for placebo, a statistically significant difference.
  • The data will be submitted for presentation at a respiratory medical conference next month.
  • The company intends to advance pamrevlumab into Phase 3 development.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News